Correction to: Regional prescription surveillance of phosphate binders in the western Saitama area: the substantial role of ferric citrate hydrate in improving serum phosphorus levels and erythropoiesis

Hiroaki Amano¹ · Yoichi Ohno^{1,2} · Tsutomu Inoue¹ · Koji Tomori¹ · Kazuya Ohama³ · Hirokazu Okada¹

Published online: 25 September 2019
 © Japanese Society of Nephrology 2019

Correction to:
Clinical and Experimental Nephrology
(2019) 23:841–851
<https://doi.org/10.1007/s10157-019-01715-8>

In the Original publication, Under the Table 1, the number of participants in the April has been incorrectly published as 1373. The corrected table is given below:

Table 1 Patient characteristics

Characteristics	April	September	<i>p</i> value
Participants	1374		
Sex (male %)	63		
Age	68 [60–76]		
Dialysis vintage	6 [3–10]		
Etiology of renal failure (%)			
Diabetic nephropathy	38		
Chronic glomerular nephritis	18		
Nephrosclerosis	14		

The original article can be found online at <https://doi.org/10.1007/s10157-019-01715-8>.

✉ Hirokazu Okada
hirookda@saitama-med.ac.jp

¹ Department of Nephrology, Faculty of Medicine, Saitama Medical University, 38, Morohongo, Moroyama-machi, Irumagun, Saitama, Japan

² Community Health Science Center, Saitama Medical University, 38, Morohongo, Moroyama-machi, Irumagun, Saitama, Japan

³ Hemodialysis Unit, Saitama Medical University, 38, Morohongo, Moroyama-machi, Irumagun, Saitama, Japan

Characteristics	April	September	<i>p</i> value
Polycystic kidney disease	5		
ANCA associated vasculitis	0.8		
Others	24		
PTX history (%)	1		
BMI (kg/m ²)	21.3 [19.2–23.8]	21.2 [19.1–23.9]	< 0.001
GNRI (%)	95 [89–101]	94 [89–100]	0.01
BUN (mg/dL)	63 ± 14	59 ± 14	< 0.001
Cr (mg/dL)	10.5 ± 2.7	10.6 ± 2.6	0.2
Alb (g/dL)	3.6 [3.4–3.8]	3.6 [3.4–3.8]	0.02
Corrected Ca (mg/dL)	9.1 [8.7–9.6]	9.2 [8.8–9.6]	0.01
Serum phosphorus (mg/dL)	5.4 [4.7–6.2]	5.2 [4.5–6.0]	< 0.001
I-PTH (pg/dL)	147 [83–213]	127 [76–210]	< 0.001
Hb (g/dL)	10.8 [10.2–11.4]	10.8 [10.2–11.4]	0.8
Ferritin (ng/mL)	56 [24–134]	64 [24–144]	0.08
TSAT (%)	26 [18–40]	27 [19–43]	0.04
Kt/V	1.4 [1.3–1.6]	1.5 [1.3–1.6]	< 0.001

Unless otherwise indicated, the values for continuous variables are presented as mean ± standard deviation or median (interquartile range). We choose an appropriate test, either the paired *t* test or Wilcoxon signed-rank test, as per the distribution of the variable

ANCA antineutrophil cytoplasmic antibody, PTX parathyroidectomy, BMI body mass index, GNRI geriatric nutritional risk index, BUN blood urea nitrogen, Cr serum creatinine, Alb serum albumin, I-PTH intact parathyroid hormone, Corrected Ca corrected serum calcium, TSAT transferrin saturation, Hb hemoglobin